| Prev Close | 1.69 |
| Day Low/High | 1.64 / 1.71 |
| 52 Wk Low/High | 1.51 / 9.55 |
| Avg Volume | 1.05M |
| Exchange | NASDAQ |
| Shares Outstanding | 52.31M |
| Market Cap | 88.41M |
| EPS | -2.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, announced today that Company...
The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 3,020,486 share decrease in total short interest for Advaxis Inc , to 5,217,154, a decrease of 36.67% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces financial results for the three months ended...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the upcoming release of financial results...
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLMN, CENX, MMYT, ULH, USM Downgrades: CVV, DGICA, DGICB, INT, MELI, RMAX, VLP Initiations: ADXS Read on to get TheStreet Quant Ratings' detailed report:
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, announced today the pricing of...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies has submitted a conditional Marketing Authorization...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that data from an earlier Phase 2 clinical study of...
The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 751,352 share increase in total short interest for Advaxis Inc , to 8,236,371, an increase of 10.04% since 12/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the Company's...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated...
I continue to believe that biotech and biopharma stocks will outperform in 2018.
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today provides a business update and announces its...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will release financial results for...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that company management will participate in...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, has received approval for a $4.
The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 1,568,524 share decrease in total short interest for Advaxis Inc , to 8,368,164, a decrease of 15.79% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Here's what you need to know now for Wednesday, Sept. 27.
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced its company overview at the Cantor Fitzgerald Global...
Investors in Advaxis Inc saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADXS options chain for the new November 17th contracts and identified the following call contract of particular interest.
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced two abstracts were selected for presentation at...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Anthony Lombardo, interim chief executive officer,...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today provided a business update and announced its financial...
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced three abstracts were selected for presentation at...
